November 6, 2026
Amgen's Repatha cut heart attack risk by 20 percent compared with ezetimibe in a large real-world study.
What happened
Amgen's cholesterol drug Repatha lowered the risk of heart attacks by 20 percent versus ezetimibe in a large real-world study. The result comes amid broader market stress, with volatility spiking 12.2 percent and oil down 13.0 percent over the past week. Yet Amgen shares were flat on the day, moving less than 1 percent.
Why it matters
The study gives real-world weight to Repatha's benefit over a cheap generic, which could shift doctor prescribing and unlock insurance coverage that has been tight. A 20 percent reduction in heart attacks is a concrete claim on a massive market, and it strengthens Amgen's hand in price negotiations with payers.
The case against
The market shrugged, with Amgen shares unmoved. Repatha's sales have long disappointed because payers restrict access, and one retrospective study may not break that logjam unless it changes guidelines or formulary placement.
What settles it
Whether major insurers or pharmacy benefit managers update their Repatha coverage criteria in the next quarter.